142 related articles for article (PubMed ID: 31278808)
1. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
[TBL] [Abstract][Full Text] [Related]
4. The direct costs of treating human visceral leishmaniasis in Brazil.
Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Liposomal Amphotericin B for All Confirmed Cases of Human Visceral Leishmaniasis in Brazil: A Budget Impact Analysis.
Silva Ferreira de Carvalho IP; Peixoto HM; Sierra Romero GA; Fernandes de Oliveira MR
Value Health Reg Issues; 2020 Dec; 23():77-84. PubMed ID: 32961526
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient.
Vechi HT; Sousa ASV; Cunha MAD; Shaw JJ; Luz KG
Am J Trop Med Hyg; 2020 Feb; 102(2):268-273. PubMed ID: 31872796
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
8. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis.
Mistro S; Gomes B; Rosa L; Miranda L; Camargo M; Badaró R
Trop Med Int Health; 2017 Dec; 22(12):1569-1578. PubMed ID: 29078022
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
[TBL] [Abstract][Full Text] [Related]
12. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.
Serbate Borges Portela Á; Margotto Bertollo C; da Silva Praxedes MF; Silva Brasileiro SA; Moreira Reis AM; Parreiras Martins MA
J Clin Pharm Ther; 2020 Jun; 45(3):573-576. PubMed ID: 31793023
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B as a treatment for human leishmaniasis.
Balasegaram M; Ritmeijer K; Lima MA; Burza S; Ortiz Genovese G; Milani B; Gaspani S; Potet J; Chappuis F
Expert Opin Emerg Drugs; 2012 Dec; 17(4):493-510. PubMed ID: 23167833
[TBL] [Abstract][Full Text] [Related]
16. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
Brito NC; Machado de Assis TS; Rabello A; Cota G
PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007856. PubMed ID: 31805052
[TBL] [Abstract][Full Text] [Related]
17. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
18. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
19. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
20. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
